中文简体
中文繁体
English
العربية
ABOUT IASO
Company Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Pipeline
Technology Platforms
Manufacturing
Publictaions
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Working at IASO
Opportunities
CONTACT
NEWS
Press Release
Media Report
Search
20
2022-05
IASO Biotherapeutics’ Equecabtagene Autoleucel, the World’s First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
01
2022-03
IASO Bio’s Nanjing Manufacturing Facility Granted the Drug Manufacturing License for CAR-T Cell Therapy Products
14
2022-02
U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by IASO Bio and Innovent
11
2022-01
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
13
2021-12
IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting
26
2021-11
IASO Biotheraputics’ CT120 Granted Orphan Drug Designation by the U.S. FDA
10
2021-11
IASO Biotherapeutics and Innovent Biologics to Present New BCMA CAR-T Cell Therapy Data in Oral Presentation at ASH 2021
09
2021-11
IASO Biotheraputics Completes Enrollment of First Patient in CT120’s Phase I/II Registrational Clinical Trial
19
2021-10
IASO Bio Appoints Industry Veteran Dr. Alan Fu Chief Financial Officer
16
2021-09
IASO Biotherapeutics Secures $108 Million Series C Funding to Advance Global Development of Innovative Cell Therapies
<
5
6
7
8
9
>
